Somewhat Favorable Press Coverage Unlikely to Affect Cardiovascular Systems (CSII) Share Price
Headlines about Cardiovascular Systems (NASDAQ:CSII) have trended somewhat positive recently, according to Alpha One Sentiment Analysis. The research firm, a service of Accern, identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cardiovascular Systems earned a media sentiment score of 0.08 on Alpha One’s scale. Alpha One also assigned headlines about the medical device company an impact score of 33 out of 100, indicating that recent press coverage is unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected AlphaOne’s rankings:
- Thousands in Nashville May Be Affected by Peripheral Artery Disease (PAD) (finance.yahoo.com)
- Thousands in Philadelphia May Be Affected by Peripheral Artery Disease (PAD) (finance.yahoo.com)
- Thousands in Dallas May Be Affected by Peripheral Artery Disease (PAD) (finance.yahoo.com)
- Thousands in Phoenix May Be Affected by Peripheral Artery Disease (PAD) (finance.yahoo.com)
- Cardiovascular Systems (CSII) to Voluntary Recall Saline Infusion Pump (streetinsider.com)
Shares of Cardiovascular Systems (NASDAQ:CSII) traded up 3.21% during midday trading on Thursday, hitting $29.22. 205,955 shares of the company’s stock were exchanged. Cardiovascular Systems has a 52 week low of $13.16 and a 52 week high of $29.70. The firm’s market cap is $952.63 million. The company has a 50-day moving average of $27.93 and a 200-day moving average of $25.85.
Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings results on Wednesday, January 25th. The medical device company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The firm earned $50 million during the quarter, compared to analysts’ expectations of $49.72 million. Cardiovascular Systems had a negative net margin of 14.74% and a negative return on equity of 15.34%. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.47) earnings per share. Equities research analysts expect that Cardiovascular Systems will post ($0.09) EPS for the current fiscal year.
CSII has been the subject of a number of research reports. Zacks Investment Research lowered shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a research note on Thursday, March 16th. Needham & Company LLC lifted their target price on shares of Cardiovascular Systems from $27.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, January 26th. Finally, Lake Street Capital initiated coverage on shares of Cardiovascular Systems in a research note on Monday, January 30th. They set a “buy” rating and a $40.00 target price for the company. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $33.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Unlikely to Affect Cardiovascular Systems (CSII) Share Price” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-unlikely-to-affect-cardiovascular-systems-csii-share-price/1206080.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.